Linking flowability and granulometry of lactose powders

F Boschini1, V Delaval2, K Traina3

  • 1APTIS, Institute of Physics, University of Liege, Sart-Tilman, B-4000 Liège, Belgium; GreenMat, Institute of Chemistry, University of Liege, B-4000 Liège, Belgium.

Related Concept Videos

Flow Table Test01:12

Flow Table Test

The flow table test is an established method used to assess the workability of concrete, particularly useful for evaluating highly flowable concrete mixes. This test employs an apparatus that consists of a wooden board topped with a steel plate, collectively weighing 35 pounds. The board is connected to a base via a hinge and measures 27.6 inches on each side.
Concrete is placed within a truncated cone mold that is 8 inches high with an 8-inch base diameter and a 5-inch top diameter. The...
978
Flow Cytometry01:23

Flow Cytometry

The development of flow cytometry techniques began in 1934 with initial attempts by Andrew Moldavan, a bacteriologist who counted the cells in a flowing capillary system. Moldavan pumped cells through a capillary tube focused under a microscope for visualization. The invention of photometry allowed the measurement of differentially-stained cells, and Louis Kamentsky developed the first multiparameter flow cytometer in 1965 to identify and count the cancer cells in cervical tissue specimens.
In...
17.5K
Laminar Flow01:27

Laminar Flow

Laminar flow represents a smooth, orderly fluid motion where particles move along parallel paths, resulting in minimal mixing between layers. Streamlined particle paths characterize this flow regime and occur under conditions where viscous forces dominate over inertial forces. The distinction between laminar, transitional, and turbulent flow is primarily determined by the Reynolds number, a dimensionless quantity calculated as:
2.6K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
216